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Hard lessons from Alzheimer’s Disease (AD) drug discovery 
The number of people affected by Alzheimer’s Disease (AD) are estimated to be a staggering 
14 million in the USA alone, and 100 million worldwide by 2050.1 Accordingly, there is an urgent 
need to discover and develop new therapeutic drugs to prevent, delay the onset, halt the 
progression, or improve the symptoms of AD.2 Regrettably, research focused on the development 
of AD therapies is having a very poor success rate.3,4 Up to now, only 5 drugs are approved for 
treatments of the symptoms of AD. No new drugs have been approved since 2003 and there are 
no approved disease-modifying drugs for AD.5 As a comparison, the success rate for the 
development of oncological compounds is approximately 19%, which drives pharma companies 
to invest mainly in areas other than AD. In addition, failures of drugs that created high expectation, 
such as Verubecestat (MK-8931).6-8 Semagacestat, (mAb) Bapineuzumab9 and the passive 
immunity drug Solanezumab (Eli Lilly)10 that reached phase III, are even casting doubts about the 
validity of the amyloid hypothesis11 of AD and driving big pharma such as Pfizer to withdraw from 
dementia research.12-13  
Many explanations for the very low rate of success of drug development for AD have been 
proposed. Lack of predictive validity of animal models, inadequate or incomplete understanding 
of the biology of AD, slowness in recruitment for trials and heterogeneity of patients, testing single 
therapies where combinations may be compulsory, wrong treatment target, incorrect drug doses, 
test therapies applied  in too advanced disease stages, lack of reliable biomarkers for the myriad 
affected biochemical processes, wrong choice of clinical endpoints, lack of efficacy of 
experimental therapies, appearance of unacceptable side effects, lack of new chemical entities 
(NCEs) resulting in few candidates entering Phase I, may be valid reasons.5, 14-17 
New approaches are clearly needed in to overcome this high rate of attrition of compounds 
for AD. Possibilities include the development of hypotheses derived from better disease 
knowledge, candidate lead compounds, repurposed drugs, immunotherapy, physical 
interventions and/or improved clinical trials. Thus, with the aim to contribute new candidate drugs 
that, after preclinical tests, may feed the currently exhausted pipeline of drugs in phase I for AD, 
here we describe a methodological approach to screen for novel and existing chemical entities 
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Comparison to other assays to study A self-assembly process in the presence of other 
chaperone or non-chaperone proteins. Advantages of our assay. 
 
Several methods, either tracking the amyloid associated toxicity in cell lines or the amyloid 
aggregation in vitro, are used to screen anti-Alzheimer anti-amyloid drugs. Only some of them 
have been extrapolated to study the A self-assembly process in the presence of chaperone or 
non-chaperone proteins. Some examples reported in the literature to study binary protein-
protein interactions, are:  
a) Fluorescence Anisotropy to study the interaction between the retinol-binding protein and 
TTR,1 
b) Surface Plasmon Resonance (SPR) studies using Aβ as a ligand immobilized in the chips 
surface,2 
c) Electrochemical strategies to study the interaction between A peptides and gelsolin.3, 4 
d) Thioflavin-T fluorescence assays to study BSA/A interactions5 and, more recently, the 
interaction between protein tau and A6   
 
Of these described procedures, only a scarce minority have been used to explore ternary 
interactions. Some examples found in the literature are: a) the ThT study of a blocking peptide of 
the ApoE/Aβ interaction;7,8 b) the study of the interference of the Retinol-Binding Protein (RBP) 
in the TTR/Aβ interaction;9 c) the SPR study of the influence of unsaturated fatty acids on 
HSA/Aβ(1-40/1-42) interactions;10 and d) the ThT study of other molecules suppressing the 
HSA/Aβ(1-40) interactions.11 In contrast with SPR based methods, our assay is performed in 
solution and no need for A immobilization is required.  
 
Additionally, our assay has the following advantages:  
a) The entire process is run in a 96-well format, minimizes sample handling and mimics 
physiological conditions such as temperature and pH in vitro. 
b) It makes use of Aβ(12-28) which has analogous properties as Aβ(1-42), but is a less 
expensive more stable peptide, and makes use of recombinant TTR.  
c) By UV monitoring of the turbidity for 6 h in the HTS assay, the chaperoning potency of 




d) The assay has been checked for reproducibility by statistical analysis and validated 
against of a small set of previously assayed good TTR ligands that behave as efficient 
small-molecule chaperones of the TTR−Aβ interactions. 
 
The rapid and simple HTS assay developed in this work is robust, reproducible and provides 
quantitative information on the aggregation process and helps at identifying novel chaperones of 
the TTR−Aβ interaction. Furthermore, the assay could be of use and implemented to evaluate 
other Aβ-binding proteins. 
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The Aβ(12−28) peptide 
 
The short Aβ amyloid peptide (VHHQKLVFFAEDVGSNK) has been extensively studied and is 
reported to exhibit essentially identical neurotoxic behavior and fibril formation features as the 
Aβ(1-42) and (1-40) peptides and thus has been used as a short model of the full Aβ 
peptides.[1]Structural studies of this Aβ(12-28) amyloid sequence have shown to contain a domain 
known as the “hydrophobic core” (residues 17-21) and a β-turn (residues 22-28).[2] These peptide 
stretches look essential for the formation of large aggregates and fibrils in the A(1-40) and A(1-
42) longer peptides.[3] Thus, mutations in the hydrophobic core such as Phe19/Pro19 have a large 
influence on the aggregation properties and even prevent fibrillization.[4] Also, the aggregation 
characteristics of Aβ(12−28) have a strong pH dependence.[5] The conformational characteristics 
of the Aβ(12-28) amyloid peptide have been studied extensively.[6]  Molecular dynamic studies[7] 
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Chemical compounds.  
Dimethyl sulfoxide (DMSO); N-(2-hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES); 
glycine; Tris(hydroxymethyl)-aminomethane (Tris); TFA, Trifluoroacetic acid and dimethyl 
sulfoxide (DMSO) were acquired from Sigma Aldrich. All commercially available solvents and 
reagents were used without further purification. N,N´-Dimethylformamide (puriss. p.a., >99.8%) 
(DMF), 1-hydroxybenzotriazol (HOBt) for peptide synthesis, >99.8%) (NMP), dichloromethane 
(reagent grade, >99.5%) (DCM), methanol (reagent grade, >99.5%), trifluoroacetic acid (reagent 
grade, >98%) (TFA), piperidine (reagent grade, >98%), and N,N´-diisopropylcarbodiimide (99%) 
(DIC), Triisopropylsilane (TIS), were purchased from standard sources.  
The small-molecule compound iododiflunisal (IDIF), an iodinated analogue of the NSAID 
diflunisal was synthesized in our lab IQAC-CSIC following our reported procedures.1The NSAIDs 
diflunisal (DIF) and N-(3,5-dichlorophenyl)anthranilic (DCPA) were from Sigma Aldrich. (diflunisal, 
D3281; DCPA, D8942; purity ≥98%). The small-molecule N-(3,5-difluorophenyl)anthranilic (DFPA) 
was prepared in our lab as previously described.2 Purity of all final compounds was proved to be 
≥95% by means of HPLC, HR-MS, and NMR techniques. Stocks of compounds assayed as small 
molecule ligands were dissolved in DMSO (ACS spectrophotometric grade, Sigma 154938) to a 
final 10 mM concentration. Working solutions of ligands were prepared by taking an aliquot of 50 
µl of the DMSO (5%) stock solution and diluting it with 950 µl of buffer A (25 mM HEPES buffer, 
10 mM glycine, pH 7.4 was prepared in the absence of salt), ratio (1:20), equivalent to a 500 µM 
concentration of ligand.  
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Recombinant wild-type human (wt rhTTR) production and purification 
 
Recombinant wild-type hTTR was produced using a pET expression System. Human wild type 
rhTTR gene was cloned into a pET expression system and transformed into E. coli BL21(DE3) 
Star. The phTTRwt-I/pET-38b(+) plasmid was kindly provided by Prof. Antoni Planas (IQS, URL). 
The expressed protein only contains an additional methionine on the N-terminus if compared to 
the mature natural human protein sequence. wt rhTTR protein was expressed in E. coli BL21-
(DE3) cells harbouring the corresponding plasmid. Expression cultures in 2xYT rich medium 
containing 100 µg/mL kanamycin were grown at 37 °C to an optical density (at 600 nm) of 4 
(OD600≈4), then induced by addition of IPTG (1 mM final concentration), grown at 37 °C for 20 
h, and harvested by centrifugation at 4 ºC, 10000 rpm for 10 min and resuspended in cell lysis 
buffer (0,5 M Tris-HCl, pH 7.6). Cell disruption and lysis were performed by French press followed 
by a sonication step at 4ºC. Cell debris were discarded after centrifugation at 4ºC, 11000 rpm for 
30 min. Intracellular proteins were fractionated by ammonium sulfate precipitation in three steps. 
Each precipitation was followed by centrifugation at 12ºC, 12500 rpm for 30 min. The pellets were 
analysed by SDS-PAGE (14% acrylamide). The TTR-containing fractions were resuspended in 
20 mM Tris-HCl, 0.1 M NaCl, pH 7.6 (buffer A) and dialyzed against the same buffer. It was 
purified by Ion exchange chromatography using a Q-Sepharose High Performance (Amersham 
Biosciences) anion exchange column and eluting with a NaCl linear gradient using 0.1M NaCl in 
20 mM Tris-HCl pH 7.6 buffer A to 0.5 M NaCl 20 mM Tris-HCl pH 7.6 (buffer B). All TTR-enriched 
fractions were dialyzed against deionized water in three steps and were lyophilized. The protein 
was further purified by gel filtration chromatography using a Superdex 75 prep grade resin (GE 
Healthcare Bio-Sciences AB) and eluting with 20 mM Tris pH 7.6, 0.1 M NaCl. Purest fractions 
were combined and dialyzed against deionized water and lyophilized. The purity of protein 
preparations was >95% as judged by SDS-PAGE. Average production yields were 150-200 mg 
of purified protein per liter of culture. Protein concentration was determined 
spectrophotometrically at 280 nm using calculated extinction coefficient value of 17780 M-1.cm-
1 for wtTTR. The protein was stored a -20ºC (See Scheme S1). A full description of this procedure 












CENTRIFUGATION AND DISCARD PELLET
PURIFICATION STEP:
AMMONIUM SULFATE PRECIPITATION








2xYT media (Kn 100µg/mL)
4°C, 10000 rpm, 10 min
E. coli BL21(DE3) cells 
French Press at 20 Kpsi and Sonication at 60% amplitude
cycles of 45 sec (1 second pause each of 3 seconds)
12°C, 12500 rpm, 30 min






Buffer A: Tris 20 mM, 0.1 M NaCl pH 7.6
Buffer B: Tris 20 mM, 0.5 M NaCl pH 7.6
(14% acrylamide)
Deionized water at 4°C in 3 steps of 8 h





Protein expression and purification 
 
Following the protocol shown in Scheme S1 we obtained 150 mg of wtTTR/L culture. Purity of wt 
rhTTR was checked by SDS-PAGE and mass spectrometry (MS). Our sequence has a molecular 
mass of 13910 Da and contains an additional methionine of 149,21 Da on the N-terminus, 
compared to the mature natural human protein sequence which has an average molecular mass 
of 13762 Da.) (See Figure S1). As shown in the Figure the wt rhTTR obtained has > 98% of purity 














Characterization of wtTTR by MALDI-TOF MS 
 
Protein solution and sinapinic acid (SA) matrix (saturated solution of SA in 30:70 v/v acetonitrile: 
water at 0.1 % TFA) were mixed at 1:1 ratio. A volume of 0.5 µL of the previous mixture was 
deposited into a polished stainless-steel target (Bruker) and allowed to dry. The deposited sample 
was washed with 0.1 % TFA solution and allowed to dry again. Finally, 0.5 µL of SA matrix were 
deposited into the washed sample and allowed to dry. Same procedure was done for the Protein 
Standard Calibration I solution (Bruker). The target was introduced in a Microflex MALDI-TOF 
(Bruker), spectra was acquired in lineal mode (Flex Control, Bruker) and processed (Flex 
















Figure S2. MALDI-ToF MS. Mass spectrum of wtTTR, both unmodified form 13915 Da and Cys-
































The following stock solutions were used: Buffer A: 25 mM HEPES buffer, 10 mM glycine, pH 7.4 
was prepared in the absence of salt. Protein (TTR) stock: 9,5 mg/mL (170 M) in 25 mM HEPES 
buffer, 10 mM glycine, pH 7.4 and 5% DMSO (final concentration) was prepared in the absence 
of salt (buffer A). For the A peptide stock: 0,4 mg/mL (200 M) in 25 mM HEPES buffer, 10 mM 
glycine, pH 7.4 and 5% DMSO (final concentration). For the small-molecule compound IDIF, a 
first solution of 3,76 mg/mL (10 mM) in DMSO was prepared. The final stock of the small-molecule 
IDIF was prepared by mixing 50 µL of the previous DMSO solution with 950 µL of buffer A (the 
final concentration of 5% DMSO). 
First, the small-molecule compound and TTR complex was formed. To this end, 60 µL of 
TTR stock was dispensed into the wells of a 96-well microplate. 40 µL of small-molecule stock 
was added to give final concentrations of 100 µM. The plate was introduced in the microplate 
reader (SpectraMax M5 Multi-Mode Microplate Readers, Molecular Devices Corporation, 
California, USA) and incubated for 1h at 37 °C with orbital shaking 15 s every 30 min. Then, 100 
L of Aβ solution was added to the well to give a final concentration of 100 M. 
Other wells of the 96-well microplate are filled with: a) Buffer alone: 200 µL of buffer A 
solution was added to the well; b) Negative control of A aggregation: 200 µL of Aβ(1-11) stock 
solution in buffer A was dispensed into the wells; c) Testing TTR aggregation: 60 µL of TTR stock 
were dispensed into the wells of a 96-well microplate and 140  µL of buffer A were added; d) For 
the Aβ(12-28) aggregation: 100 µL of Aβ(12-28) stock solution is dispensed into the wells and 
100 µL of buffer A were added.   
The plate was incubated at 37 °C in a thermostated microplate reader with orbital shaking 
15 s every minute for 30 min. The absorbance at 340 nm was monitored for 6 h at 30 min intervals. 
Data were collected and analyzed using Microsoft Excel software. All assays were done in 
duplicate.  
 
𝑅𝐴(%) = [1 − (
𝐴𝑏𝑠𝑐
𝐴𝑏𝑠Aβ + 𝐴𝑏𝑠𝑐
)] ∗ 100                         (1) 
 
The parameter monitored in this assay was used to calculate the percent reduction of formation 
of aggregates (RA %) according to equation 1, where AbsAβ and Absc are the final absorbance of 







Turbidity assay: stock solutions  
 
Other wells of the 96-well microplate are filled with: a) Buffer alone: 200 µL of buffer A solution 
was added to the well; b) Negative control of A aggregation: 200 µL of Aβ(1-11) stock solution 
in buffer A was dispensed into the wells; c) Testing TTR aggregation: 60 µL of TTR stock were 
dispensed into the wells of a 96-well microplate and 140  µL of buffer A were added; d) For the 
Aβ(12-28) aggregation: 100 µL of Aβ(12-28) stock solution is dispensed into the wells and 100 




Scheme S2. Representation of the microplate with different samples before Turbidity assay. 
 
Preliminary experiments 
Turbidity assays: Aggregation kinetics of Aβ(12-28)  
 
Figure S3. Aβ(12-28) aggregation monitored by turbidity assay at 37 °C over 6 h at pH 7.4 in 25 mM HEPES 
buffer, 10 mM glycine and 5% DMSO (final concentration) at 37 ºC. Aggregation kinetics of: Aβ(12-28) alone 
(100 M) (dark blue line); Aβ(12-28) (50 M) in the presence of TTR (50 M) (blue line) (ratio 2:1); and 
Aβ(12-28) (100 M) in the presence of the complex TTR/IDIF (TTR 50 M; IDIF 100 M)  (ratio 2:1:2) (green 
line). Samples were assayed in duplicate and are representative of three different replicates (n=6). Negative 




Design of experiments (DoE)  
Factorial designs are one of the most important DoE because they produce efficient 
experiments that allow observation of responses to one factor at different levels of other factors 
in the same experiment.1,2 They allow the investigation of the main effect of factors but also their 
interactions (when factors do not act independently of others). Factors are types of treatments 
(quantitative or qualitative) which have several levels. The Factorial design consists of all possible 
combinations of the levels of several factors. These combinations (runs) are defined and randomly 
ordered and realized in the laboratory, obtaining therefore the value of the response variable (Y) 
for each factor’s combination. Behind the Factorial design a statistical model is defined: an 
Analysis of Variance (ANOVA) model. Several sums of squares are constructed to estimate the 
effects of factors and their interactions on Y. Tests of hypotheses about factor effects and their 
interactions are also calculated to determine the statistical significance. More than one replicate 
of each combination of the experiment is needed to estimate the variance error. To reduce the 
experimental error variation a method called blocking can achieve more precision. Blocking 
consists of introducing an additional factor called block which is an external variable to the 
treatments and that creates a stratification of the runs into homogeneous groups. The block effect 
can be also introduced into the statistical model and be estimated. The statistical software used 
was JMP 12.1.0 (SAS Institute).3 
 
1. Kuehl, R. O. Design of experiments: statistical principles of research design and analysis. 2nd ed.; 
Duxbury/Thomson Learning Pacific Grove: CA, 2000. 
2. Box, G. E. P.; Stuart Hunter, J.; Hunter, W.G. Statistics for Experimenters: Design, Innovation, and 
Discovery. 2nd ed.; Wiley-Interscience: New Jersey, 2005. 
3. JMP ®, Version 12.1.0. SAS Institute Inc., Cary, NC, USA. 
 
Method development and optimization 
The variable to be maximized has been the absorbance. Preliminary investigations were carried 
out to select initial analysis conditions, taking into account that temperature and ionic strength 
may have a nonlinear effect on the fibril formation, we have considered these two factors in a 
two–level design, the temperature at 37 ºC and 40 °C and the ionic strength ([NaCl]) at 0 and 100 
mM. The concentration was considered at three levels 50, 100 and 200 µM, because we wish 
identified the sensitivity for our method. The UV absorption maxima for Aβ-peptide fibril formation 
is achieved at 340, 360 and 405 nm. The flow layout of a Design of Experiments for method 

















Scheme S3. Flow layout in Design of Experiments (DoE). 
Turbidimetry 




















Spectral scanning of Aβ(12-28)  
 
Figure S4. Spectral scanning of a 200 µM solution of Aβ(12-28). The blue trace corresponds to 
the initial clean solution (Si) and the green to the same solution after 6h at 37ºC that became 
turbid (Sf). Three different experiments were conducted with duplicate samples (n=6).*** Studies 
performed at pH 7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final concentration) 
at 37 ºC. 
Factorial design by applying JMP software 
 
A factorial design was applied in our analysis (Table S1). Initial number of experiments was 48, 
creating the matrix design described in Table S2. We modified the initial matrix design adding a 
column to study the effect of different batches of peptide, as a block effect. Randomizing all runs 
we realized the experiments in the laboratory and the measured values of absorbance for each 
run were obtained (Table S2). In some of these combinations (3-+, 3+- and 3++) it was not 
possible to obtain the absorbance. 
The Table S3 shows the initial 48 numbers of experiments, plus 2 replicates that were explored 
for the 2-- combination on the 2nd level of the block (factors’ selected conditions). To confirm 
results at these selected set of conditions, six more runs (n=6) were randomly done and analyzed, 
in order to ensure reproducibility of the previous results. 
Analysis of variance (ANOVA) results of the adjusted model are shown in Table S4. Results 
shown as the model is globally statistically significant (p < 0.0001). Goodness of fit measures as 
R squared values (RSq), the root mean square error (RMSE) and graphs between the original 
absorbance and predicted absorbance were analyzed. The significance of the parameters in the 
model is shown in Table S2. 
It was found that all the main factors (concentration, ionic strength and temperature) and the 
interactions between concentration and the other two factors were statistically significant but not 
the temperature versus ionic strength interaction. As expected, the block factor was not 
statistically significant (Table S5). 
Table S1. Design levels of factors. 
Factor1 Low level High level Midpoint 
Concentration (µM) 50 200 100 
Temperature (°C) 37 40 * 
Ionic strength (mM of NaCl) 0 100 * 



















Table S2. Matrix design of the experimental runs.  
Run Concentration Temperature Ionic Strength Block 
1−− 50 37 0 1 
1−+ 50 37 100 1 
1+− 50 40 0 1 
1++ 50 40 100 1 
2−− 100 37 0 1 
2−+ 100 37 100 1 
2+− 100 40 0 1 
2++ 100 40 100 1 
3−− 200 37 0 1 
3−+ 200 37 100 1 
3+− 200 40 0 1 
3++ 200 40 100 1 
1−− 50 37 0 1 
1−+ 50 37 100 1 
1+− 50 40 0 1 
1++ 50 40 100 1 
2−− 100 37 0 1 
2−+ 100 37 100 1 
2+− 100 40 0 1 
2++ 100 40 100 1 
3−− 200 37 0 1 
3−+ 200 37 100 1 
3+− 200 40 0 1 
3++ 200 40 100 1 
1−− 50 37 0 2 
1−+ 50 37 100 2 
1+− 50 40 0 2 
1++ 50 40 100 2 
2−− 100 37 0 2 
2−+ 100 37 100 2 
2+− 100 40 0 2 
2++ 100 40 100 2 
3−− 200 37 0 2 
3−+ 200 37 100 2 
3+− 200 40 0 2 
3++ 200 40 100 2 
1−− 50 37 0 2 
1−+ 50 37 100 2 
1+− 50 40 0 2 
1++ 50 40 100 2 
2−− 100 37 0 2 
2−+ 100 37 100 2 




2++ 100 40 100 2 
3−− 200 37 0 2 
3−+ 200 37 100 2 
3+− 200 40 0 2 
3++ 200 40 100 2 
 
Table S3. JMP data table of Complex Factorial Design runs with their corresponding measured 
responses of absorbance.  
Run1 Concentration Temperature Ionic Strength Block Absorbance 
1−− 50 37 0 1 0,0449 
1−+ 50 37 100 1 0,0497 
1+− 50 40 0 1 0,0673 
1++ 50 40 100 1 0,0656 
2−− 100 37 0 1 0,1197 
2−+ 100 37 100 1 0,1206 
2+− 100 40 0 1 0,1152 
2++ 100 40 100 1 0,1239 
3−− 200 37 0 1 0,1617 
3−+ 200 37 100 1 * 
3+− 200 40 0 1 * 
3++ 200 40 100 1 * 
1−− 50 37 0 1 0,0457 
1−+ 50 37 100 1 0,0486 
1+− 50 40 0 1 0,0552 
1++ 50 40 100 1 0,0592 
2−− 100 37 0 1 0,1188 
2−+ 100 37 100 1 0,1193 
2+− 100 40 0 1 0,1134 
2++ 100 40 100 1 0,1208 
3−− 200 37 0 1 0,1692 
3−+ 200 37 100 1 * 
3+− 200 40 0 1 * 
3++ 200 40 100 1 * 
1−− 50 37 0 2 0,0555 
1−+ 50 37 100 2 0,0516 
1+− 50 40 0 2 0,0557 
1++ 50 40 100 2 0,0581 
2−− 100 37 0 2 0,114 
2−+ 100 37 100 2 0,126 
2+− 100 40 0 2 0,1256 
2++ 100 40 100 2 0,1292 
3−− 200 37 0 2 0,1773 
3−+ 200 37 100 2 * 
3+− 200 40 0 2 * 




1−− 50 37 0 2 0,059 
1−+ 50 37 100 2 0,0548 
1+− 50 40 0 2 0,0565 
1++ 50 40 100 2 0,0591 
2−− 100 37 0 2 0,1132 
2−+ 100 37 100 2 0,1249 
2+− 100 40 0 2 0,1283 
2++ 100 40 100 2 0,1304 
3−− 200 37 0 2 0,1716 
3−+ 200 37 100 2 * 
3+− 200 40 0 2 * 
3++ 200 40 100 2 * 
2−− 100 37 0 2 0,125 
2−− 100 37 0 2 0,1219 
2−− 100 37 0 2 0,1264 
2−− 100 37 0 2 0,1237 
2−− 100 37 0 2 0,126 
2−− 100 37 0 2 0,1278 
1Original runs (48) plus 6 additional replicates. 
 










F Ratio Prob > F 
Model 0,057 7 0,0082 67,8353 < 0,0001* 
Error 0,0044 30 0,00012   










In the prediction profile JMP software automatically adjusts the graph to display the optimal 
settings at which the best response of the absorbance is obtained. The factors temperature and 
ionic strength did have a significant but poor effect on the absorbance response. Block factor was 
not statistically significant.  
Table S5. Analysis of variance results for the different factors and their interactions in the 
turbidimetric assay.  
 
Source of variation Log Utility 
p-value1 
Concentration 16,444 0,000 
Concentration*Ionic strength 2,917 0,001 
Ionic Strength 1,713 0,019 
Temperature 1,698 0,020 
Concentration*Temperature 1,368 0,043 
Block effect 0,974 0,106 
Temperature*Ionic strength 0,018 0,959 





Turbidity assays: Aggregation kinetics of Aβ(12-28) and Aβ(1-42) peptides up to 
18 h: 
a) in the presence and absence of IDIF; b) in the presence of TTR; and c) in the 
presence of TTR + IDIF 
 
 
Figure S6:   
A) Inhibition of Aβ(12-28) aggregation monitored by turbidity assay at 37 °C over 18 h. 
Aggregation kinetics of: Aβ(12-28) alone (dark violet line); Aβ(12-28) in the presence of IDIF (red 
line); Aβ(12-28) in the presence of TTR (blue line); and Aβ(12-28) in the presence of the complex 
TTR/IDIF (green line).  
B) Inhibition of Aβ(1-42) aggregation monitored by turbidity assay at 37 °C over 18 h. Aggregation 
kinetics of: Aβ(1-42) alone (dark violet line); Aβ(1-42) in the presence of IDIF (red line); Aβ(1-42) 
in the presence of TTR (blue line); and Aβ(1-42) in the presence of the complex TTR/IDIF (green 
line). Samples were assayed in duplicate and are representative of three different replicates 
(n=6). Negative controls (buffer solutions) are not shown. (Fig. S6B was included in the 





Turbidity assays: aggregation kinetics of A(1-42) with A(12-28) at two different 
concentrations followed by Turbidity assays. 
 
 
Figure S7: Aggregation kinetics of A peptides by Turbidity assay at 37 °C over 10 h.: Aβ(1-42) 
alone (dark blue line); Aβ(12-28) (100 M) (light blue line); Aβ(12-28) (50 M) (bright blue line); 
and Aβ(1-42) and Aβ(12-28) in the presence of the complex TTR/IDIF (green lines). Samples 
were assayed in duplicate and are representative of three different replicates (n=6). Negative 
controls (buffer solutions) are not shown 
A similar comparison of the aggregation kinetics of different A peptides, including 
A(12-28), was reported using ThT assays with A(1-40), A(1-42), and A(12-28) at 
100 M (Sadowski et al. 2004, page 941). 
M. Sadowski, J. Pankiewicz, H. Scholtzova, J. A. Ripellino, Y. Li, S. D. Schmidt, P. M. Mathews, J. 
D. Fryer, D. M. Holtzman, E. M. Sigurdsson, T. Wisniewski. A synthetic peptide blocking the 
apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and 






Thioflavin-T (ThT) fluorescence assays 
The robustness of our turbidimetry-based method was further validated on the basis of 
comparative by Thioflavin-T (ThT) fluorescence assays on the same system. The ThT 
fluorescence was monitored at 37 °C using Gemini XPS plate reader (Molecular Devices) at an 
excitation wavelength of 440 nm and an emission wavelength of 490 nm. Thioflavin-T (ThT) was 
dissolved in 25 mM HEPES buffer, 10 mM glycine, pH 7.4 and 5 % DMSO to a final concentration 
of 10M. Aggregation of Aβ(1-42) 20 μM was performed in the presence of 10 μM ThT. All 
solutions were dissolved in the same buffer. TTR was added to a final concentration of 10 μM. 
IDIF was added to a final concentration of 20 μM. For the ternary complex, TTR was incubated 
first with IDIF for 1h, then Aβ(12-28) was added. The final volume was 200 μL for all samples. 
Fluorescence intensity at 490 nm of each sample was monitored after each 2h for 8h, and then 
at 21h. Measurements were performed as independent triplicates. Recorded values were 
averaged and background measurements (buffer containing 25 M ThT) were subtracted. 
Measurements were performed as independent triplicates. Recorded values were averaged and 
background measurements (buffer containing 25 M ThT) were subtracted. 
 
Thioflavin T studies: Aggregation kinetics of A(12-28) and A(1-42) 
Aggregation kinetics of Aβ(12-28) (Figure S8A) and Aβ(1-42) peptide (Figure S8B):  
alone; in the presence of TTR or in the presence of TTR stabilized with different small-
molecule compounds. 
 
Figure S8A: ThT assays of the aggregation of Aβ(12-28) alone (50 M), in complex with TTR 
(25 M), or in complex with TTR stabilized with different small compounds (50 M),  (TTR/IDIF, 
TTR/DCPA and TTR/DFPA). ThT fluorescence was measured at 37 ºC each 10 min for 3h, then 
each 20 min from 3 h to 6 h, and then at 8 h. Samples were assayed in duplicate and are 
representative of three different replicates (n=6). Negative controls (buffer solutions) are not 
shown.  















































Figure S8B: ThT assays of the aggregation of Aβ(1-42) alone (20 M), in complex with TTR (10 
M), or in complex with TTR stabilized with different small compounds (20 M),  (TTR/IDIF, 
TTR/DIF,  TTR/Tafamidis, TTR/DCPA and TTR/DFPA). ThT fluorescence was measured at 37 
ºC each 10 min for 3h, then each 20 min from 3 h to 6 h, and then at 8 h. Samples were assayed 
in duplicate and are representative of three different replicates (n=6). Negative controls (buffer 
solutions) are not shown.  
Transmission Electron Microscopy (TEM) 
Aβ(12-28) peptide (100 μM), alone or with TTR (20 M) (alone or pre-incubated with IDIF for 
1 hour at 37 °C) was incubated at 37 °C for 48 h. For visualization by TEM, 5 µl sample aliquots 
were absorbed to carbon-coated collodion film supported on 200-mesh copper grids, for 5 
minutes, and negatively stained with 1% uranyl acetate. Grids were exhaustively examined with 
a JEOL JEM-1400 transmission electron microscope equipped with an Orious Sc1000 digital 
camera.  
 
Morphological analysis of aggregates and of their cell toxicity: TEM studies 
It is well established that Aβ peptide, in particular its oligomeric form, is toxic to cells 
leading to apoptosis and cellular death. Previous work has demonstrated that TTR 
protects against this neurotoxicity.1-3 
1.  R. Costa, A. Gonçalves, M. J. Saraiva, I. Cardoso, Transthyretin binding to A-Beta peptide--
impact on A-Beta fibrillogenesis and toxicity. FEBS Lett., 2008, 582, 936-942. 
2.  L. Nilsson, A. Pamrén, T. Islam, K. Brännström, S. A. Golchin, N. Pettersson, I. Iakovleva, L. 
Sandblad, A. L. Gharibyan, A. Olofsson, Transthyretin Interferes with Aβ Amyloid Formation by 
Redirecting Oligomeric Nuclei into Non-Amyloid Aggregates. J. Mol. Biol. 2018, 430, 2722-2733. 
3.  S. A. Ghadami, S. Chia, F. S. Ruggeri, G. Meisl, F. Bemporad, J. Habchi, R. Cascella, C. M. 
Dobson, M. Vendruscolo, T. P. J. Knowles, F. Chiti, Transthyretin inhibits primary and secondary 
nucleation of amyloid-β peptide aggregation and reduces the toxicity of its oligomers. 
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TEM studies: Aβ(12-28) in the presence of TTR and of the TTR/IDIF complex.  
(reported in Cotrina et al. J. Med. Chem. 63, 6, 3205-3214 (2020). 
To assess the structure of the Aβ(12-28) species generated in the presence of TTR and of the 
TTR/IDIF complex, we performed a morphological analysis by transmission electron microscopy 
(TEM). The ultrastructural examination confirmed the known facts [perhaps reference needed] 
that after 48 h of incubation at 37 °C, Aβ(12-28) formed highly ordered and structured fibrils. In 
Figure S9A, it is possible to appreciate that fibrils are formed by several protofilaments, laterally 
assembled (arrow) or twisted over each other (arrowhead). In the presence of TTR only round 
particles and thin and shorter fibrils were detected (Figure S9B, arrow and arrowhead, 
respectively). When TTR was previously incubated with IDIF the inhibitory effect was more 
pronounced and only round and small particles were observed (Figure S9C). 
 
  
Figure S9. Morphologic assessment by TEM of the influence of TTR on Aβ(12-28) fibrillization. 
A)  Aβ(12-28) after 48 h of incubation at 37 °C; B) Aβ(12-28) in the presence of TTR; and C) 





Toxicity studies: Aβ(1-42) in the presence of TTR and of the TTR/IDIF complex  
 
Cell culture and caspase-3 assay  
SH-SY5Y cells (human neuroblastoma cell line; European Collection of Cell Cultures) were 
propagated in 25-cm2 flasks and maintained at 37 °C in a 95% humidified atmosphere and 5% 
CO2. Cells were grown in Dulbecco’s minimal essential medium supplemented with 10% fetal 
bovine serum (Gibco BRL). Activation of caspase-3 was measured using the CaspACE 
fluorimetric 96-well plate assay system (Sigma), following the manufacturer’s instructions. Briefly, 
10 μM Aβ(1-42) (Genscript) pre-incubated for 48 h at 4 °C with shaking, in F12 media (Gibco 
BRL) with or without 2 μM TTR (alone or previously incubated with IDIF (20 μM) for 1 h at 37 °C), 
were added to 80% confluent cells, cultured in 6-well plates, in Dulbecco’s minimal essential 
medium with 1% fetal bovine serum, and further incubated for 24 h, at 37 °C. Subsequently, each 
well was trypsinized and the cell pellet was lysed in 100 μl of hypotonic lysis buffer (Sigma). Forty 
μL of each cell lysate were used in duplicates for determination of caspase-3 activation. The 
remaining cell lysate was used to measure total cellular protein concentration with the Bio-Rad 
protein assay kit (Bio-Rad), using BSA as standard. Values shown are the mean of duplicates 
and the experiment was performed twice. Comparison between groups was made using the 
Student’s t-test. A P value of less than 0.05 was considered statistically significant. 
 
As depicted in Figure S10, we confirmed that TTR prevented the noxious effect of the Aβ(1-
42) peptide, reducing in about 45% the levels of caspase-3 activation, as compared to the levels 
produced by the oligomers, although the reduction was not enough to reach the values obtained 
in the control with media alone. Importantly, TTR stabilized by IDIF was even more potent and 
caspase-3 levels were reduced in over 60%, as compared to the oligomers. Again, the caspase-
3 levels were not as low as the control but were significantly lower than those of measured in cells 
incubated with Aβ co-incubated with TTR (without IDIF).  
 
Altogether, these results confirm that TTR is a neuroprotective protein, preventing Aβ 
fibrillogenesis and toxicity, and that TTR performance can be enhanced by small-molecule 
chaperones of the TTR/A interaction, thus validating our high-throughput assay, and prompting 
TTR stabilization as a promising therapeutic strategy in AD. 
 
 
Figure S10. Caspase-3 activation in cell culture. Aβ(1-42) oligomers (10 μM), TTR (2 μM), or 
Aβ(1-42) co-incubated at 4 °C for 48 h with TTR alone or TTR complexed with IDIF (20 μM) for 1 
h at 37 °C, were then added to SH-5YSY cultured cells and further incubated for 24 h at 37 °C. *, 
# and & denote significance as compared to control, to Aβ(1-42) oligomers and to Aβ(1-42) + 






The quality of an assay for HTS can be evaluated based on the Z’-factor which reflects the 
separation in mean values for the high and low controls while taking into consideration the 
variability within each group.1 A Z’ factor below zero indicates poor quality assay with no 
separation between the high and low controls. A Z’ factor value between 0.5 and 1 indicate an 
excellent quality assay with large separation between the high and low controls. Preferably, 
optimized assays have a Z’ value above 0.5. The statistical Z’-factor can be calculated using 
equation 2: 
 
𝑍′ = 1 −  
3𝑆𝐷 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒+3𝑆𝐷 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
|𝑚𝑒𝑎𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒−𝑚𝑒𝑎𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙|
       (2) 
where sample is the highest RA% for Aβ(12-28) in presence of the binary complex (TTR+IDIF) or 
TTR alone, and the control is the Aβ(12-28) aggregation. “Mean” is the mean value of the 
aggregation after 6 h, and SD is the standard deviation. 
 
1. J. H. Zhang, T. D. Chung and K. R. A. Oldenburg, Simple Statistical Parameter for Use in Evaluation 
and Validation of High Throughput Screening Assays. J. Biomol. Screen., 1999, 4, 67-73. 
 
Amyloid peptides.  
 
Aβ(1-42) peptide  
In order to prevent the spontaneous formation of aggregates in solution, we have used the depsi-
Aβ(1-42) peptide (Genscript,  RP10017-1), a chemically-modified β-amyloid (1-42) precursor. 
This depsipeptide precursor is converted into the corresponding native Aβ(1-42) peptide by a 
change in pH (1, 2). 
References: 
1. Y. Sohma, M. Sasaki, Y. Hayashi, T. Kimura, Y. Kiso, Design synthesis of a novel water-soluble 
Aβ1-42 isopeptide: an efficient strategy for the preparation of Alzheimer’s disease-related peptide 
Aβ1–42 via O–N intramolecular acyl migration reaction. Tetrahedron Lett. 2004, 45, 5965-5968. 
 
2. M. Beeg, M. Stravalaci, A. Bastone, M. Salmona, M. Gobbi, A modified protocol to prepare seed-
free starting solutions of amyloid-β (Aβ) 1-40 and Aβ 1-42 from the corresponding depsipeptides. 
Anal. Biochem. 2011, 411, 297-299. 
Other amyloid sequences 
The amyloid peptide sequences Aβ(1-11) and Aβ(12-28) were purchased from Bachem AG 
(Switzerland) as trifluoroacetate salts (ref. H-2956 and H-7910, respectively). The Aβ(12-28) 
peptide was also synthesized by microwave solid-phase peptide synthesis (MW-SPPS) using 
Fmoc chemistry using the corresponding Fmoc protected amino acids. Cleavage from resin was 
performed using TFA/H20/TIS (95:2,5:2,5) (V:V:V) and the peptide was precipitated with tert-butyl 
methyl ether. The peptide was purified by RP-HPLC using a VersaFlash® system and 
characterized by analytical RP-HPLC and MALDI-TOF-MS and compared to the commercial 





Synthesis of Abeta (12-28)  
 
The peptide was synthesized both by conventional SPPS and by microwave MW-SPPS 
conditions. 
General procedure for conventional manual Solid-Phase Peptide Synthesis (SPPS). Amino 
acids, building blocks, coupling reagents and prederivatized Fmoc-Lys(Boc)-Wang resin  (0.7 
mmol/g) were purchased from Novabiochem AG. All reagents used for synthesis were from 
analytical grade.  
The peptide was synthesized manually following standard solid phase methods and Fmoc 
protocols on Fmoc-Lys(Boc)-Wang prederivatized resin using amino acids with orthogonal 
protections on lateral chains. Amide couplings were performed manually in a peptide synthesis 
column using DIC/HOBt in DMF under reciprocal oscillating agitation. Coupling efficiencies were 
monitored by Kaiser ninhydrin test. Fmoc groups were removed with a 20% piperidine in DMF 
solution.  
Peptides were cleaved from the resin by shaking with a cleavage cocktail consisting of 
TFA:H2O:TIS (95:2.5:2.5) for 2 h. The filtrate was evaporated, washed several times with ice-cold 
tert-butyl methyl ether and concentrated under reduced pressure. The crude peptide was 
precipitated with ice-cold tert-butyl methyl ether, filtered, redissolved in water and lyophilized. 
Crude peptide was purified by C-18 RP-HPLC (VersaFlashTM Flash Chromatography system) 
using a water-acetonitrile gradient and followed by lyophilization. The final pure peptide was 
characterized by MALDI-ToF MS and UPLC-ToF MS. Analytical RP-HPLC were performed using 
the following solvents A (0.1% TFA in H2O) and B (0.1% TFA in acetonitrile) and the Nucleosil 
100 RP-18 (5µm) C18 column (4x 250 mm). The retention time was compared to a commercially 
available sample from Novabiochem. 
General procedure for Microwave Solid Phase Peptide Synthesis (MW-SPPS). 
We followed similar procedures as describe in the literature:  
B. Bacsa S. Bosze C. O. Kappe Direct solid-phase synthesis of the beta-amyloid (1-42) 
peptide using controlled microwave heating. J. Org. Chem. 2010, 75, 2103-2106.  
Equipment: CEM Liberty Blue system on a 0.1 mmol scale using Fmoc-Lys(Boc)Wang resin   (0.7 
mmol/g) and a 5-fold excess of reagents [0.2 M amino acid solution (in DMF) with 0.5 M DIC (in 
DMF) and 1.0 M Oxyma (in DMF) or 0.45 M HBTU (in DMF) and 2.0 M DIEA (in NMP with 10 fold 
excess)]. 
Using CEM for the synthesis of Abeta (12-28) two coupling procedures were used:  
a) The “single coupling” procedure for all amino acids except Histidines at 75ºC; and 
 
b) the “Double 50 c coupling” was used for Histidine. The sensitive FmocHis(Trt)-OH 
residues were built to into the sequence switching from 75ºC  to room temperature  in 
order to minimize racemization using an extended reaction time of 60 min and applying 






















Characterization of Abeta (12-28): HPLC and MS.  
HPLC analysis  
Analytical RP-HPLC with a Nucleosil 100 RP-18 (5µm) C18 column (4x 250 mm). Flow rate: 
1mL/min. Solvents used: A: 0.1% TFA in H2O; B: 0.1% TFA in acetonitrile 
Gradient: From A:B (80:20) to A:B (20:80) in 25 min.  
RT (BACHEM SAMPLE, REF 4014778) = 9.19 min 
 
Figure S11: Analytical HPLC of Abeta(12-28) from Bachem. 
After VersaFlashTM RP-HPLC purification 
From A:B (80:20) to A:B (20:80) in 25 min.  RT  = 9.1 min 
 
Figure S12: HPLC of purified Abeta(12-28) obtained by SPPS. 
  





















- (M+3H)+3 = 652,3432
- (M+2H)+2 = 978,0109




Isothermal Titration Calorimetry (ITC) studies:  




Figure S14: ITC analysis of the interactions: A) the binary complex TTR + Aβ(12-28); B) the 
ternary complex of [TTR + DCPA)] and Aβ(12-28). All these ITC studies were performed at pH 
7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final concentration) at 25 ºC. 
 
Table S6: Thermodynamic parameters for the Aβ(12-28) / TTR interaction and the 










TTR + Aβ(12-28) 1 3,1 -4,52 3,23 -7,76 
(TTR + DCPA) + Aβ(12-28) 1 1,1 -2,25 5,84 -8,09 

























Isothermal Titration Calorimetry (ITC) studies:  





Figure S15: ITC analysis of the interactions: A) the binary complex TTR + Aβ(12-28); B) the 
ternary complex of [TTR + DFPA)] and Aβ(12-28). All these ITC studies were performed at pH 
7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final concentration) at 25 ºC. 
 
Table S7: Thermodynamic parameters for the Aβ(12-28) / TTR interaction and the ternary 










TTR + Aβ(12-28) 1 3,1 -4,52 3,23 -7,76 
(TTR + DFPA) + Aβ(12-28) 1 0,6 -2,24 6,07 -8,30 

























Preliminary data for additional compounds using the HTS system:  
 
Triiodophenol, Epigallocatechin gallate (EGCG), Resveratrol (RESV) and the 






Figure S16. Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 37 °C over 6 
h. A) Aggregation of A(12-28): in the presence of TTR (binary complex) and in the presence of  
TTR + IDIF (ternary complex) and in the presence of  TTR + TIP (ternary complex)  . Studies were 
performed at pH 7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final concentration) 
at 37 ºC. B) Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 37 °C over 6 h 
in the presence of TTR, in the presence of IDIF and in the presence of TIP. 
Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin 
amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996, 
93(26):15051-6. doi: 10.1073/pnas.93.26.15051.  
Dolado, I.; Nieto, J.; Saraiva, M. J. M.; Arsequell, G.; Valencia, G.; Planas, A. Kinetic assay 
for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J. 
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Figure S17. Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 37 °C over 6 
h. A) Aggregation of A(12-28): in the presence of TTR (binary complex) and in the presence of  
TTR + IDIF (ternary complex) and in the presence of  TTR + RESV (ternary complex) . Studies 
were performed at pH 7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final 
concentration) at 37 ºC. B) Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 
37 °C over 6 h in the presence of TTR, in the presence of IDIF and in the presence of RESV. 
Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of 
potent human transthyretin amyloid disease inhibitors [published correction appears in Nat 
Struct Biol 2000 May;7(5):431]. Nat Struct Biol. 2000, 7312-321. doi:10.1038/74082. 
 
Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier 
PM. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into 
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Epigallocatechin gallate (EGCG)  
 
 
Figure S18. Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 37 °C over 6 
h. A) Aggregation of A(12-28): in the presence of TTR (binary complex) and in the presence of  
TTR + IDIF (ternary complex) and in the presence of  TTR + EGCG (ternary complex)  . Studies 
were performed at pH 7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final 
concentration) at 37 ºC. B) Aggregation kinetics of Aβ(12-28) measured by the turbidity assay at 
37 °C over 6 h in the presence of TTR, in the presence of IDIF and in the presence of EGCG. 
Miyata M., Sato T., Kugimiya M., Sho M., Nakamura T., Ikemizu S., Chirifu M., Mizuguchi 
M., Nabeshima Y., Suwa Y., et al. The crystal structure of the green tea polyphenol (-)-
epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the 
thyroxine binding site. Biochemistry. 2010; 49, 6104–6114. doi: 10.1021/bi1004409. 
 
Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the 
process of transthyretin (TTR) amyloid fibril formation. FEBS Lett. 2011, 585, 2424-30. 
 
Gimeno, A., Santos, L.M.; Alemi, M.; Rivas, J.; Blasi, D.;  Cotrina, E.Y.; Llop, J.; Valencia, 
G.; Cardoso, I.; Quintana, J.; Arsequell, G.; Jiménez-Barbero, J. Insights on the Interaction 
between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR 
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Figure S19: ThT assays of the aggregation of Aβ(1-42) alone (20 M), in complex with TTR (10 M), or in 
complex with TTR stabilized with different small compounds (20 M)  (TTR/Tolcapone, and  TTR/Tafamidis). 
ThT fluorescence was measured at 37 ºC each 10 min for 3h, then each 20 min from 3 h to 6 h, and then at 
8 h. Samples were assayed in duplicate and are representative of three different replicates (n=6). Negative 
controls (buffer solutions) are not shown.  
The following ITC study on the repurposed drug tolcapone is included at the Supporting 
Information in a recent paper that will be published in Journal of Alzheimer's Disease (JAD). 
(https://www.j-alz.com/vol77-1): Oral Treatment with Iododiflunisal Delays Hippocampal 
Amyloid-β Formation in a Transgenic Mouse Model of Alzheimer’s Disease: A Longitudinal 
in vivo Molecular Imaging Study. Luka Rejc, Vanessa Gómez-Vallejo, Xabier Rios, Unai 
Cossío, Zuriñe Baz, Edurne Mujica, Tiago Gião, Ellen Y. Cotrina, Jesús Jiménez-Barbero, Jordi 








Figure S20: ITC analysis of the interactions: A) the binary complex TTR + Aβ(12-28); B) the ternary complex 
of [TTR + TOLCAPONE)] and Aβ(12-28); and C) the ternary complex of [TTR + IDIF)] and Aβ(12-28).. All 
these ITC studies were performed at pH 7.4 in 25 mM HEPES buffer, 10 mM glycine and 5% DMSO (final 






























Kd     0.81 µM
ΔG -8.31 Kcal/mol
ΔH -2.48 Kcal/mol
TΔS 5.83 Kcal/mol
